Gangliosidosis Clinical Trials

1 recruiting

About Gangliosidosis Clinical Trials

Looking for clinical trials for Gangliosidosis? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gangliosidosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gangliosidosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Gangliosidoses, GM2Gangliosidosis, GM1
Azafaros A.G.75 enrolled36 locationsNCT07082543
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

GM1 GangliosidosisGM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.147 enrolled37 locationsNCT07054515
Recruiting
Phase 2

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

GM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.21 enrolled3 locationsNCT07399704
Recruiting

A Natural History Study of the Gangliosidoses

GM1 GangliosidosisGM2 GangliosidosisSandhoff Disease+2 more
University of Minnesota52 enrolled1 locationNCT00668187
Recruiting

Longitudinal Study of Neurodegenerative Disorders

Gaucher DiseaseBatten DiseaseLeukodystrophy+24 more
University of Pittsburgh1,500 enrolled1 locationNCT03333200
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Lysosomal DiseasesGangliosidosisGM1
National Human Genome Research Institute (NHGRI)54 enrolled1 locationNCT03952637
Recruiting

The Myelin Disorders Biorepository Project

AdrenoleukodystrophyCockayne SyndromeRefsum Disease+63 more
Children's Hospital of Philadelphia12,000 enrolled23 locationsNCT03047369
Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Myasthenia GravisAmyloidosisAlpha-Thalassemia+14 more
xCures1,000 enrolled1 locationNCT06539169